Roche counts on its tried-and-true cancer drugs Rituxan, Avastin and Herceptin to bring home the bacon, and the meds did not disappoint in 2015. But despite the drugs' strong performance, Roche still missed on profits last year, disheartening news for the company as it readies itself for biosimilar competition to some of its top sellers.
Citing safety and quality concerns, Swiss-based Roche has won a temporary injunction from the Delhi High Court to block the expected launch of a biosimilar of breast cancer drug Herceptin (trastuzumab) by Reliance Life Sciences, the Economic Times reports.
Roche's bread-and-butter cancer drugs--Rituxan, Avastin and Herceptin--delivered once again in the third quarter, and now the Swiss drugmaker expects 2015 to turn out better than it previously had forecast.
Gilead Sciences' hep C drug Sovaldi is not yet available on mainland China, at least not legitimately. But it is in Hong Kong, and buyers who ask quietly at small pharmacies along Nathan Road can expect to get it, and many other top-tier drugs, without a prescription.
Many shoebox-sized drugstores in Hong Kong are magnets for mainland Chinese seeking access to cutting-edge oncology and hepatitis C treatments without a prescription because they are either highly expensive or not available at home in the latest twist of cross-border healthcare buying, Bloomberg reports.
Roche has been charting promising numbers for its standout breast cancer drugs Kadcyla and Perjeta. But now the next-gen duo has failed to beat Herceptin and chemo in a late-stage study, putting a damper on Roche's plan to expand the market for its new drugs and sending its shares into a downward spiral.
Genentech CEO Ian Clark is again being publicly chastised for his company's decision to move three of its best-selling cancer drugs to specialty distributors. Groups representing more than 5,000 hospitals say, besides higher costs, the move is as likely to encourage counterfeiting as to deter it.
A team from the Singapore-based Agency for Science, Technology and Research has found that a component of green tea has the potential to act as a nano-sized drug delivery vehicle to encapsulate proteins used to fight cancer.
When it comes to selling big, cancer drugs have a lot going for them. Their targets--deadly diseases that in many cases can kill quickly--put them in high demand, even as they continue to redefine...
European authorities recently warned that stolen vials of Roche's cancer med Herceptin were showing up across the continent, some containing little or no active ingredient. Now they say the thefts were not isolated incidents, but commissioned by an organized crime group in Italy.